Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

30 Apr 2014

Abstract excerpt

The development of targeted therapies has revolutionized the treatment of cancer patients. The identification of "druggable" oncogenic kinases and the creation of small-molecule inhibitors designed to specifically target these mutant kinases have become an important therapeutic paradigm across several different malignancies. Often these inhibitors induce dramatic clinical responses in molecularly defined cohorts....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Melanoma and MAPK Pathways
Share to Quinazolinone synthesis and applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24789032
DOI: 10.1158/1078-0432.ccr-13-1610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesPMID 24789032Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapiesSemantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.Semantic proximity Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

Managing Resistance to EFGR- and ALK-Targeted Therapies.Semantic proximity Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read ↗

Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerSemantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.